ABSTRACT

Background
Clinical and hematological features of beta-thalassemia are modulated by different factors resulting in a wide range of clinical severity that mainly include the type of disease-causing mutation, alpha-globin and gamma-globin chain production ability. In the present study we investigate the respective contribution of known modifiers to the prediction of betathalassemia clinical severity as assessed by the age at first transfusion of patients.
Design and Methods
We studied the effect of seven loci in a cohort of 316 beta0-thalassemia Sardinian patients. In addition to characterizing the beta-globin gene mutations, alpha-globin gene defects and HBG2:g.-158C>T polymorphism, we genotyped two different markers at the BCL11A gene and three in the HBS1L-MYB intergenic region using SNP microarrays, imputation and direct genotyping. We performed Cox proportional hazard analysis of the time to first transfusion.
Results
According to the resulting model, we were able to explain phenotype severity to a large extent (Harrell's C-index=0.72; Cox & Snell R 2 =0.394) and demonstrated that most of the model discriminatory ability is attributable to the genetic variants affecting fetal hemoglobin production (HBG2:g.-158C>T, BCL11A and HBS1L-MYB loci: C-index=0.68, R 2 =0.272), while the remaining is due to alpha-globin gene defects and gender. Consequently, significantly distinct survival curves can be described in our population.
Conclusions
This detailed analysis clarifies the impact of genetic modifiers on clinical severity of the disease measured by time to first transfusion by determining their relative contributions in a homogeneous cohort of beta0-thalassemia patients. It may also support clinical decisions regarding the beginning of transfusion therapy in patients with beta-thalassemia.
INTRODUCTION
Beta-thalassemia is characterized by a decreased or absent beta-globin chain synthesis due to a variety of mutations that result in an excess of alpha-globin chains, which precipitate in red blood cells' precursors in the bone marrow, causing their premature death.
(1) In Sardinia, the most common type is a nonsense mutation at codon 39 of the beta-globin gene (HBB:c118C>T). (2) The majority of patients manifest a severe form of anemia (thalassemia major) and are transfusion dependent from the first years of life. This retrospective study was conducted in accordance with the Declaration of Helsinki and the patients gave informed consent for the DNA analysis.
SNPs selection
We selected five SNPs from the HBS1L-MYB intergenic region and the BCL11A locus known to be associated with Hb F levels, as follow (see Table 2 ):
rs1427407: the most significant SNP associated with Hb F levels within BCL11A, as reported in Menzel et al. 2007. (12) This SNP is in high linkage disequilibrium (LD) with rs766432 (r 2 =0.98) in our sample, and with rs4671393 (r 2 =0.88 / D'=1) in the CEU samples based on 1000 Genomes Project pilot phase 1 (CEU.1kG), for which effects on Hb F levels are also well-documented. (13, 14) rs10189857: within BCL11A, documented to have an independent effect on Hb F levels.
rs9399137: the most significant SNP for Hb F levels within the HBS1L-MYB intergenic region in different population (5, 12) , in complete LD with a 3-bp deletion located in close proximity to four erythropoiesis-related transcription factors binding sites. (15, 16) rs4895441: a SNP within the HBS1L-MYB intergenic region, widely reported to be associated with Hb F levels (5, 17) and in complete LD with rs9402686 (r 2 =1 / D'=1 from CEU.1kG data), also reported to be independently associated with Hb F levels. (15) rs6904897: within the HBS1L-MYB intergenic region, this SNP is in complete LD with rs28384513 (r 2 =1 / D'=1 from CEU.1kG data), reported to be independently associated with Hb F levels. (15) Genotyping DNA was extracted from venous peripheral blood with standard methods.
Mutation analysis of the beta-globin gene was performed by direct DNA sequencing.
The HBG2:g.-158C>T polymorphism was determined as described. (18) Alpha-globin gene defects were determined using GAP-PCR or restriction enzyme digestion for deletional and non-deletional defects, respectively. (19) SNPs were directly genotyped except for rs4895441 that was genotyped using the polymorphism) for which SNP array data were not available, were genotyped using TaqMan SNP genotyping assay (Applied Biosystems, Warrington, UK) for each of the five SNPs.
Quality controls
Microarrays data underwent quality control procedures on samples including: sample call rate (CR) (exclusion when CR<95%), cryptic relatedness (exclusion of first degree relatives), inbreeding coefficient (exclusion if negative with CR<98%) and reported gender versus heterozygosity of X chromosome SNPs (exclusion if discordant). Principal component analysis as implemented in EIGENSTRAT was performed for outliers detection. (21) Quality controls attributes for the SNPs used in the present study are described in Table   2 .
Statistical analysis
All genome-wide quality control measures were performed using the PLINK software package, version 1.07 (22) while the SPSS statistical software package, version 18.00
(SPSS, IBM, Somers, NY, USA), was used for subsequent analysis.
All markers selected for the present study were entered in a backward stepwise Cox proportional hazard model to characterize their effect on time to first transfusion, together with gender, alpha-globin gene defects and status for HBG2:g.-158C>T polymorphism (only -/-and +/-genotypes were observed for this SNP). A variable was defined for each SNP with values 0, 1, or 2 according to the number of copies of the less frequent allele, except for rs6904897: showing no difference between G/G and G/T genotypes survival curves it was codified 0 in these cases and 1 otherwise. Alpha-globin gene defects were classified as 0, 1, or 2 according to the number of deleted or mutated copies of the HBA gene (see Table 1 for details). Gender was codified 0 if female and 1 if male. Covariates were excluded from the model when their p-value was greater than 0.10.
Patients were considered uncensored when blood transfusion occurred during the study and censored when blood transfusion did not occur. We report Cox and Snell R 2 as well as
Harrell's concordance index (C-index) to assess how well the model performed.
RESULTS
Results from the stepwise Cox proportional hazard model are presented in Following this classification, 50% of patients in the fourth quartile group underwent their first transfusion within six months of life, whereas only 3% of patients in the first quartile group had started transfusions by the same age. In this group it took more than six years to reach 50% of patients that started transfusion, whereas by the same age all patients had undergone their first transfusion in the fourth quartile group. In the first quartile group, 47% of patients never started red blood cells' transfusion (see Figure 1 ).
All survival curves were significantly different from each other (p<0.01, Breslow's test). In particular, the third quartile group was significantly different from the fourth quartile group (p<0.001) and the second quartile group was significantly different from both the first and third quartile risk-groups (p<0.001 and p=0.007 respectively).
DISCUSSION
The present study aimed at measuring the influence of known genetic modifiers of beta0-thalassemia on phenotype severity assessed as time to first transfusion. To this aim, SNPs in the BCL11A gene and HBS1L-MYB intergenic region were selected based on previous studies and genotyped in a group of 316 patients, as well as alpha-globin gene defects and HBG2:g.-158C>T polymorphism. All these variables, together with gender, were included in a Cox proportional hazard model for time at first transfusion, and their respective effects were measured. Results showed a substantial impact of Hb F production variants and alpha-globin gene defects on beta-thalassemia phenotype severity, allowing to predict the risk of patients to start transfusion at different times of their life.
In this study we assumed that the time to first transfusion accurately reflects variations in beta-thalassemia phenotype severity. Such hypothesis seems to be supported by our results, as all variables and the hierarchy of their effects agree with previous studies on genetic modifiers of both Hb F levels and beta-thalassemia clinical severity, even though other unknown genetic factors and clinical conditions might be co-responsible for need of transfusion. (3, 11, 15, 23, 24) To the best of our knowledge, the present study is the first to analyze the severity of betathalassemia in a quantitatively defined manner and to account for such complete set of known predictors. In a previous study, Galanello et al. (11) The authors report no potential conflict of interest. First quartile (patients with more positive predictors combinations) 1 Second quartile 1 Third quartile 1 Fourth quartile (patients with more negative predictors combinations) 1
